<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499056</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Bone-008</org_study_id>
    <nct_id>NCT01499056</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint</brief_title>
  <official_title>Evaluation the Side Effect of Bone Marrow Derived Mesenchymal Stem Cell in Patients With Osteoarthritis of Hip Joint</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis of the hip is a common type of osteoarthritis which can cause significant
      problems. First-line of management for patient with osteoarthritis consists of weight
      reduction, education, and analgesic medication. If necessary, invasive treatment like total
      hip replacement are performed for the patient. The objective of this study was to assess the
      safety of bone marrow mesenchymal stem cells (BM-MSCs) implantation in patients with hip
      osteoarthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase one clinical study designed to investigate the safety of intra-articular
      injection of cultured autologous BM-MSCs in patients with severe hip osteoarthritis candidate
      for total hip replacement. All subjects will undergo bone marrow aspiration. Autologous MSCs
      will be extracted and cultured for 4 weeks. Patients will receive intra-articular injection
      of cultured MSCs under the guide of fluoroscopy. Paraclinical studies (X-Ray and MRI) will be
      done before and 6 months after treatment. Pain relief and functional improvement of the joint
      will be assessed by VAS, WOMAC, and Harris Hip Score questionnaire before treatment, and 2
      and 6 months after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>swelling of hip joint</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluatin the swelling of hip joint by physical examination after intra articular injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>deterioration of joint function</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation deterioration of joint function by physical examination after intra articular cell injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>skin allergic reaction</measure>
    <time_frame>1 week</time_frame>
    <description>Evaluation the skin allergic reaction like erythema,rash,swelling after intra articular cell injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory reaction</measure>
    <time_frame>1 week</time_frame>
    <description>Evaluation the Respiratory reaction like dyspenea by physical examination after imtra articular cell injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative changes in pain intensity</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation Quantitative changes in pain intensity measured by Visual Analogue Scale after intra articular cell injection 2 months after cell transplantation in compare with base line (before injection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical function improvement</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation the physical function improvement Measured by WOMAC osteoarthritis index and Harris Hip Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subchondral bone edema</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation the subchondral bone edema by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cartilage thickness</measure>
    <time_frame>2 months</time_frame>
    <description>measuring the cartilage thickness after cell transplantation by MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>hip osteoarthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with hip joint osteoarthritis who underwent cell injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>stem cell injection</intervention_name>
    <description>intra articular inection of mesenchymal stem cell</description>
    <arm_group_label>hip osteoarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoarthritis diagnosed by MRI

          -  End stage osteoarthritis candidate for total hip replacement

        Exclusion Criteria:

          -  Pregnancy or lactating

          -  Positive tests for HIV, HCV, HBV

          -  Active neurologic disorder

          -  End organ damage

          -  Uncontrolled endocrine disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Royan Cell therapy Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohsen Emadeddin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>scientist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>December 21, 2011</last_update_submitted>
  <last_update_submitted_qc>December 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>hip joint</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

